STOCK TITAN

[Form 4] Cingulate Inc. Warrants Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Director Peter J. Werth of Cingulate received a stock option grant for 15,000 shares of common stock on June 20, 2025. The options were granted with an exercise price of $4.14 per share and will expire on June 20, 2035.

Key terms of the option grant:

  • Vesting occurs at the earlier of: one-year anniversary of grant date or the 2026 annual stockholder meeting
  • Transaction reported as a Form 4 filing indicating changes in beneficial ownership
  • Options were acquired at no cost ($0) as part of director compensation

The filing was signed by Shane J. Schaffer as attorney-in-fact on June 23, 2025. This equity grant appears to be part of standard director compensation arrangements and represents a new beneficial ownership position for the reporting person.

Il direttore Peter J. Werth di Cingulate ha ricevuto una concessione di opzioni su azioni per 15.000 azioni ordinarie il 20 giugno 2025. Le opzioni sono state concesse con un prezzo di esercizio di 4,14 $ per azione e scadranno il 20 giugno 2035.

Termini chiave della concessione delle opzioni:

  • Il vesting avviene al primo tra: il primo anniversario della data di concessione o l'assemblea annuale degli azionisti del 2026
  • La transazione è stata riportata tramite un deposito Form 4 che indica variazioni nella proprietà effettiva
  • Le opzioni sono state acquisite senza alcun costo ($0) come parte della compensazione del direttore

Il deposito è stato firmato da Shane J. Schaffer in qualità di procuratore il 23 giugno 2025. Questa concessione di equity sembra far parte delle normali disposizioni di compensazione dei direttori e rappresenta una nuova posizione di proprietà effettiva per la persona che presenta la segnalazione.

El director Peter J. Werth de Cingulate recibió una concesión de opciones sobre acciones por 15,000 acciones ordinarias el 20 de junio de 2025. Las opciones se otorgaron con un precio de ejercicio de $4.14 por acción y vencerán el 20 de junio de 2035.

Términos clave de la concesión de opciones:

  • La adquisición de derechos ocurre al primero de: el aniversario de un año desde la fecha de concesión o la reunión anual de accionistas de 2026
  • La transacción se reportó mediante una presentación del Formulario 4 que indica cambios en la propiedad beneficiaria
  • Las opciones se adquirieron sin costo alguno ($0) como parte de la compensación al director

La presentación fue firmada por Shane J. Schaffer como apoderado el 23 de junio de 2025. Esta concesión de acciones parece formar parte de los arreglos estándar de compensación para directores y representa una nueva posición de propiedad beneficiaria para la persona que reporta.

이사 Peter J. Werth는 Cingulate에서 2025년 6월 20일에 15,000주의 보통주 스톡옵션을 부여받았습니다. 옵션은 주당 $4.14의 행사가격으로 부여되었으며, 2035년 6월 20일에 만료됩니다.

옵션 부여의 주요 조건:

  • 베스팅은 부여일 1주년 또는 2026년 연례 주주총회 중 빠른 시점에 발생
  • 거래는 실질 소유권 변동을 나타내는 Form 4 신고서로 보고됨
  • 옵션은 이사 보상으로 비용 없이($0) 취득됨

신고서는 2025년 6월 23일 Shane J. Schaffer가 대리인 자격으로 서명했습니다. 이 지분 부여는 표준 이사 보상 체계의 일부로 보이며, 신고자에게 새로운 실질 소유권 위치를 나타냅니다.

Le directeur Peter J. Werth de Cingulate a reçu une attribution d'options d'achat d'actions pour 15 000 actions ordinaires le 20 juin 2025. Les options ont été accordées avec un prix d'exercice de 4,14 $ par action et expireront le 20 juin 2035.

Principaux termes de l'attribution d'options :

  • L'acquisition des droits s'effectue à la première des deux dates suivantes : le premier anniversaire de la date d'attribution ou l'assemblée générale annuelle des actionnaires de 2026
  • La transaction a été déclarée via un dépôt du formulaire 4 indiquant des modifications dans la propriété bénéficiaire
  • Les options ont été acquises sans coût ($0) dans le cadre de la rémunération du directeur

Le dépôt a été signé par Shane J. Schaffer en tant que mandataire le 23 juin 2025. Cette attribution d'actions semble faire partie des arrangements standards de rémunération des directeurs et représente une nouvelle position de propriété bénéficiaire pour la personne déclarant.

Direktor Peter J. Werth von Cingulate erhielt am 20. Juni 2025 eine Aktienoptionszuteilung über 15.000 Stammaktien. Die Optionen wurden zu einem Ausübungspreis von 4,14 $ pro Aktie gewährt und laufen am 20. Juni 2035 ab.

Wichtige Bedingungen der Optionszuteilung:

  • Die Vesting erfolgt zum früheren Zeitpunkt von: dem einjährigen Jubiläum des Gewährungsdatums oder der Jahreshauptversammlung 2026
  • Die Transaktion wurde durch eine Form 4-Meldung gemeldet, die Änderungen im wirtschaftlichen Eigentum anzeigt
  • Die Optionen wurden kostenfrei (0 $) im Rahmen der Vergütung des Direktors erworben

Die Meldung wurde am 23. Juni 2025 von Shane J. Schaffer als Bevollmächtigter unterschrieben. Diese Aktienzuteilung scheint Teil der üblichen Vergütungsregelungen für Direktoren zu sein und stellt eine neue wirtschaftliche Eigentumsposition für die meldende Person dar.

Positive
  • None.
Negative
  • None.

Il direttore Peter J. Werth di Cingulate ha ricevuto una concessione di opzioni su azioni per 15.000 azioni ordinarie il 20 giugno 2025. Le opzioni sono state concesse con un prezzo di esercizio di 4,14 $ per azione e scadranno il 20 giugno 2035.

Termini chiave della concessione delle opzioni:

  • Il vesting avviene al primo tra: il primo anniversario della data di concessione o l'assemblea annuale degli azionisti del 2026
  • La transazione è stata riportata tramite un deposito Form 4 che indica variazioni nella proprietà effettiva
  • Le opzioni sono state acquisite senza alcun costo ($0) come parte della compensazione del direttore

Il deposito è stato firmato da Shane J. Schaffer in qualità di procuratore il 23 giugno 2025. Questa concessione di equity sembra far parte delle normali disposizioni di compensazione dei direttori e rappresenta una nuova posizione di proprietà effettiva per la persona che presenta la segnalazione.

El director Peter J. Werth de Cingulate recibió una concesión de opciones sobre acciones por 15,000 acciones ordinarias el 20 de junio de 2025. Las opciones se otorgaron con un precio de ejercicio de $4.14 por acción y vencerán el 20 de junio de 2035.

Términos clave de la concesión de opciones:

  • La adquisición de derechos ocurre al primero de: el aniversario de un año desde la fecha de concesión o la reunión anual de accionistas de 2026
  • La transacción se reportó mediante una presentación del Formulario 4 que indica cambios en la propiedad beneficiaria
  • Las opciones se adquirieron sin costo alguno ($0) como parte de la compensación al director

La presentación fue firmada por Shane J. Schaffer como apoderado el 23 de junio de 2025. Esta concesión de acciones parece formar parte de los arreglos estándar de compensación para directores y representa una nueva posición de propiedad beneficiaria para la persona que reporta.

이사 Peter J. Werth는 Cingulate에서 2025년 6월 20일에 15,000주의 보통주 스톡옵션을 부여받았습니다. 옵션은 주당 $4.14의 행사가격으로 부여되었으며, 2035년 6월 20일에 만료됩니다.

옵션 부여의 주요 조건:

  • 베스팅은 부여일 1주년 또는 2026년 연례 주주총회 중 빠른 시점에 발생
  • 거래는 실질 소유권 변동을 나타내는 Form 4 신고서로 보고됨
  • 옵션은 이사 보상으로 비용 없이($0) 취득됨

신고서는 2025년 6월 23일 Shane J. Schaffer가 대리인 자격으로 서명했습니다. 이 지분 부여는 표준 이사 보상 체계의 일부로 보이며, 신고자에게 새로운 실질 소유권 위치를 나타냅니다.

Le directeur Peter J. Werth de Cingulate a reçu une attribution d'options d'achat d'actions pour 15 000 actions ordinaires le 20 juin 2025. Les options ont été accordées avec un prix d'exercice de 4,14 $ par action et expireront le 20 juin 2035.

Principaux termes de l'attribution d'options :

  • L'acquisition des droits s'effectue à la première des deux dates suivantes : le premier anniversaire de la date d'attribution ou l'assemblée générale annuelle des actionnaires de 2026
  • La transaction a été déclarée via un dépôt du formulaire 4 indiquant des modifications dans la propriété bénéficiaire
  • Les options ont été acquises sans coût ($0) dans le cadre de la rémunération du directeur

Le dépôt a été signé par Shane J. Schaffer en tant que mandataire le 23 juin 2025. Cette attribution d'actions semble faire partie des arrangements standards de rémunération des directeurs et représente une nouvelle position de propriété bénéficiaire pour la personne déclarant.

Direktor Peter J. Werth von Cingulate erhielt am 20. Juni 2025 eine Aktienoptionszuteilung über 15.000 Stammaktien. Die Optionen wurden zu einem Ausübungspreis von 4,14 $ pro Aktie gewährt und laufen am 20. Juni 2035 ab.

Wichtige Bedingungen der Optionszuteilung:

  • Die Vesting erfolgt zum früheren Zeitpunkt von: dem einjährigen Jubiläum des Gewährungsdatums oder der Jahreshauptversammlung 2026
  • Die Transaktion wurde durch eine Form 4-Meldung gemeldet, die Änderungen im wirtschaftlichen Eigentum anzeigt
  • Die Optionen wurden kostenfrei (0 $) im Rahmen der Vergütung des Direktors erworben

Die Meldung wurde am 23. Juni 2025 von Shane J. Schaffer als Bevollmächtigter unterschrieben. Diese Aktienzuteilung scheint Teil der üblichen Vergütungsregelungen für Direktoren zu sein und stellt eine neue wirtschaftliche Eigentumsposition für die meldende Person dar.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Werth Peter J.

(Last) (First) (Middle)
1901 W. 47TH PLACE

(Street)
KANSAS CITY KS 66205

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cingulate Inc. [ CING ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to Buy) $4.14 06/20/2025 A 15,000 (1) 06/20/2035 Common Stock 15,000 $0 15,000 D
Explanation of Responses:
1. The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders.
/s/ Shane J. Schaffer, Attorney-in-Fact 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Peter J. Werth receive from CINGW on June 20, 2025?

Peter J. Werth received 15,000 stock options with an exercise price of $4.14 per share. These options were granted on June 20, 2025, and will expire on June 20, 2035.

When do Peter Werth's CINGW stock options vest?

The stock options vest on the earlier of two conditions: (1) the one-year anniversary of the grant date (June 20, 2026) or (2) the date of Cingulate Inc.'s 2026 annual meeting of stockholders.

What is Peter J. Werth's role at CINGW?

According to the Form 4 filing, Peter J. Werth serves as a Director of Cingulate Inc. (CING/CINGW), as indicated by the 'X' marked in the Director box under the relationship section.

What was the total value of stock options granted to Peter Werth in this CINGW insider transaction?

The Form 4 shows that Peter Werth received 15,000 stock options at an exercise price of $4.14 per share. The filing indicates the price of the derivative security was $0, meaning these were granted as compensation rather than purchased.

Where is CINGW's Director Peter Werth located?

According to the Form 4 filing, Peter J. Werth's address is listed as 1901 W. 47th Place, Kansas City, KS 66205.
Cingulate

NASDAQ:CINGW

CINGW Rankings

CINGW Latest News

CINGW Latest SEC Filings

CINGW Stock Data

3.83M
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY